The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
Iran’s foreign minister says missile programme not up for negotiation as Trump says sending more ships to the region.
Former CNN anchor Don Lemon faces federal charges under the Freedom of Access to Clinic Entrances (FACE) Act after a protest at a Minnesota church, marking a rare application of the law beyond abortion clinic demonstrations and raising First Amendment questions.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
Generating cash is just the first step. We analyze three companies to see which ones effectively convert that cash into lasting shareholder value and which ones struggle to capitalize on their financial strength.
While market darlings come and go, a select group of companies achieves sustained outperformance through a powerful trifecta: rising sales, expanding profitability, and efficient capital use. We examine three such names that have delivered triple-digit returns over the past five years.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
A trove of documents released by the U.S. Department of Justice includes emails from Jeffrey Epstein making lurid, unsubstantiated allegations about Bill Gates, while also detailing his interactions with other prominent individuals.
The Islamic State group has claimed a coordinated attack on a key airbase near Niamey's international airport, amid escalating tensions after Niger's junta leader pointed fingers at France, Benin, and Ivory Coast.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
Shares of quantum computing pioneer Rigetti Computing have delivered substantial returns over the past year, dramatically outperforming the broader market. Yet, analysts caution that sky-high valuations may have raced far ahead of the company's current commercial reality.
A social media poll by billionaire Mark Cuban reveals a near-even split on which part of U.S. health insurance is more financially painful—premiums or deductibles. The results, and the outpouring of personal stories in the replies, underscore a system many describe as forcing impossible choices amid relentlessly rising costs.
The U.S. Department of Justice has initiated a civil rights investigation into the fatal shooting of Alex Pretti by federal immigration officers in Minneapolis, a senior official confirmed Friday. The probe could lead to criminal charges, though legal hurdles remain high.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
